A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary) ; Ibrutinib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 19 Aug 2019 Planned initiation date changed (estimated date for recruitment of the first subject) from 1 Jul 2019 to 21 Aug 2019.
- 19 Aug 2019 Status changed from not yet recruiting to recruiting.
- 20 Jun 2019 Planned initiation date changed from 31 May 2019 to 1 Jul 2019.